<document>

<filing_date>
2020-03-26
</filing_date>

<publication_date>
2020-10-01
</publication_date>

<priority_date>
2019-03-27
</priority_date>

<ipc_classes>
A61K39/12
</ipc_classes>

<assignee>
BOEHRINGER INGELHEIM VETMEDICA
</assignee>

<inventors>
MUNDT, EGBERT
NIKOLIN, VELJKO
COLLADO MIGUENS, Javier
GONZÁLEZ, Fernando
CAMÓS, Laia
</inventors>

<docdb_family_id>
66175370
</docdb_family_id>

<title>
IMMUNOGENIC COMPOSITIONS AND VACCINES COMPRISING AFRICAN SWINE FEVER VIRUS PEPTIDES AND PROTEINS AND USES THEREOF
</title>

<abstract>
The present invention relates to African swine fever virus (ASFV) peptides and/or polypeptides as well as immunogenic fragments thereof, corresponding encoding AFSV oligonucleotides and/or polynucleotides as well as immunogenic fragments thereof, immunogenic compositions, vaccines and uses thereof.
</abstract>

<claims>
1. An immunogenic composition comprising
(a) one, two or more African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; and or
(b) one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or
immunogenic fragments thereof encoding African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; and/or
(c) a viral or bacterial vector, preferably a recombinant and/or non-naturally occurring viral or bacterial vector, comprising one, two or more African swine fever vims oligonucleotides and/or
polynucleotides and/or immunogenic fragments thereof encoding African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; and
(d) optionally, one or more pharmaceuticalor veterinary-acceptable carriers or excipients, preferably said one or more carriers or excipients being suitable for oral, intradermal, intramuscular or intranasal application.
2. A vaccine or pharmaceutical composition comprising
(a) one, two or more African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; and/or
(b) one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or
immunogenic fragments thereof encoding African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; and/or
(c) a viral or bacterial vector, preferably a recombinant and/or non-naturally occurring viral or bacterial vector, comprising one, two or more African swine fever vims oligonucleotides and/or
polynucleotides and/or immunogenic fragments thereof encoding African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; and
(d) one or more pharmaceuticalor veterinary-acceptable carriers or excipients, preferably said one or more carriers or excipients being suitable for oral, intradermal, intramuscular or intranasal application;
(e) optionally, said vaccine or pharmaceutical composition further comprising an adjuvant.
3. The immunogenic composition as claimed in claim 1 or the vaccine or pharmaceutical composition as claimed in claim 2, wherein according to (a) the one, two or more African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and or immunogenic fragments thereof comprise, preferably consist of, an amino acid sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570), K145R (SEQ ID NOS: 526, 524, 523, 522, 521, 520, 518, 516, 515, 514), B475L (SEQ ID NOS: 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48), H339R (SEQ ID NOS: 468, 466, 465, 464, 463, 462, 461, 460, 458, 456, 455, 454), I226R (SEQ ID NOS: 489, 487, 486, 485, 484, 483, 481, 479, 478), CP2475L (p37) (SEQ ID NOS: 266, 265, 264, 263, 262, 261), CP2475L (pl50) (SEQ ID NOS: 260, 259, 258), G1211R (SEQ ID NOS: 432, 430, 429, 428, 427, 426, 425, 424, 423, 422, 420, 418, 417, 416), M1249L (SEQ ID
NOS: 562, 561, 560, 559, 558, 557, 556, 555, 554, 553, 552, 551, 550, 549, 548, 547, 546, 545, 544, 543,
542, 541, 540, 539), MGF505-9R (SEQ ID NOS: 733, 732, 731, 730, 729, 728, 727, 726), P1192R (SEQ ID NOS: 817, 816, 815, 814, 813, 812, 811, 810, 809, 808, 807, 806, 805, 804, 803, 802, 801), MGF505- 1R (SEQ ID NOS: 692, 691, 690, 689, 688, 687, 686, 685, 684), MGF505-3R (SEQ ID NOS: 703, 702, 701, 700, 699), EP424R (SEQ ID NOS: 389, 388, 387, 386, 385, 384, 383, 382, 381, 380, 379), C475L (SEQ ID NOS: 201, 200, 199, 198, 197, 196, 195, 194, 193, 192, 191, 190, 189, 188), B602L (SEQ ID
NOS: 75, 74, 73, 72, 71, 70, 69, 68, 67), CP530R (SEQ ID NOS: 278, 277, 276, 275), D339L (SEQ ID
NOS: 322, 321, 320), D117L (SEQ ID NOS: 862, 864), I243L (SEQ ID NOS: 494, 493, 492, 491), I73R (SEQ ID NOS: 504, 503, 502), DP238L (SEQ ID NOS: 327, 326, 325), I9R (SEQ ID NOS: 513, 512, 511, 510), preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS:
274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570); and most preferably selected from the group consisting of:
MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25).
4. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 3, wherein according to (b) the one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof encode the one, two or more African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and or immunogenic fragments thereof comprising, preferably consisting of, an amino acid sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570), K145R (SEQ ID NOS: 526, 524, 523, 522, 521, 520, 518, 516, 515, 514), B475L (SEQ ID NOS: 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48), H339R (SEQ ID NOS:
468, 466, 465, 464, 463, 462, 461, 460, 458, 456, 455, 454), I226R (SEQ ID NOS: 489, 487, 486, 485, 484, 483, 481, 479, 478), CP2475L (p37) (SEQ ID NOS: 266, 265, 264, 263, 262, 261), CP2475L (pl50) (SEQ ID NOS: 260, 259, 258), G1211R (SEQ ID NOS: 432, 430, 429, 428, 427, 426, 425, 424, 423, 422, 420, 418, 417, 416), M1249L (SEQ ID NOS: 562, 561, 560, 559, 558, 557, 556, 555, 554, 553, 552, 551, 550, 549, 548, 547, 546, 545, 544, 543, 542, 541, 540, 539), MGF505-9R (SEQ ID NOS: 733, 732, 731, 730, 729, 728, 727, 726), P1192R (SEQ ID NOS: 817, 816, 815, 814, 813, 812, 811, 810, 809, 808, 807, 806, 805, 804, 803, 802, 801), MGF505-1R (SEQ ID NOS: 692, 691, 690, 689, 688, 687, 686, 685, 684), MGF505-3R (SEQ ID NOS: 703, 702, 701, 700, 699), EP424R (SEQ ID NOS: 389, 388, 387, 386, 385, 384, 383, 382, 381, 380, 379), C475L (SEQ ID NOS: 201, 200, 199, 198, 197, 196, 195, 194, 193, 192, 191, 190, 189, 188), B602L (SEQ ID NOS: 75, 74, 73, 72, 71, 70, 69, 68, 67), CP530R (SEQ ID NOS: 278, 277, 276, 275), D339L (SEQ ID NOS: 322, 321, 320), D117L (SEQ ID NOS: 862, 864), I243L (SEQ ID NOS: 494, 493, 492, 491), I73R (SEQ ID NOS: 504, 503, 502), DP238L (SEQ ID NOS: 327, 326, 325), I9R (SEQ ID NOS: 513, 512, 511, 510), preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570); and most preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25).
5. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 4, wherein according to (b) the one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof encoding African swine fever vims peptides and or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; comprise, preferably consist of, a nucleic acid sequence which is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to a nucleic acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26), A238L (SEQ ID NOS: 24, 22, 20, 18), MGF100-1L (SEQ ID NOS: 573, 571), K145R (SEQ ID NOS: 527, 525, 519, 517), B475L (SEQ ID NOS: 866, 867), H339R (SEQ ID NOS: 469, 467, 459, 457), I226R (SEQ ID NOS: 490, 488, 482, 480), CP2475L (p37) (SEQ ID NOS: 868, 869), CP2475L (pl50) (SEQ ID NOS: 870, 871), G1211R (SEQ ID NOS: 433, 431, 421, 419), M1249L (SEQ ID NOS: 872, 873), MGF505-9R (SEQ ID NOS: 874, 875), P1192R (SEQ ID NOS: 876, 877), MGF505-1R (SEQ ID NOS: 878, 879), MGF505-3R (SEQ ID NOS: 880, 881), EP424R (SEQ ID NOS: 882, 883), C475L (SEQ ID NOS: 884, 885), B602L (SEQ ID NOS: 886, 887), CP530R (SEQ ID NOS: 888, 889), D339L (SEQ ID NOS: 890, 891), D117L (SEQ ID NOS: 863, 865), I243L (SEQ ID NOS: 892, 893), I73R (SEQ ID NOS: 894, 895), DP238L (SEQ ID NOS: 896, 897), I9R (SEQ ID NOS: 898, 899), preferably selected from the group consisting of:
MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS:
858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26), A238L (SEQ ID NOS: 24, 22, 20, 18), MGF100-1L (SEQ ID NOS: 573, 571); and most preferably selected from the group consisting of: MGF505- 7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26).
6. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 5, wherein according to (c) the viral or bacterial vector is selected from the group consisting of: asfivirus viral vector, avipox vims viral vector, canine morbillivirus viral vector, herpes vims viral vector, varicella vims viral vector, Lawsonia spp., Salmonella spp.
7. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 6, wherein according to (c) the viral or bacterial vector comprises one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof, which encode one, two or more African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof comprising, preferably consisting of, an amino acid sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570), K145R (SEQ ID NOS: 526, 524, 523, 522, 521, 520, 518, 516, 515, 514), B475L (SEQ ID NOS: 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48), H339R (SEQ ID NOS: 468, 466, 465, 464, 463, 462, 461, 460, 458, 456, 455, 454), I226R (SEQ ID NOS: 489, 487, 486, 485, 484, 483, 481, 479, 478), CP2475L (p37) (SEQ ID NOS: 266, 265, 264, 263, 262, 261), CP2475L (pl50) (SEQ ID NOS: 260, 259, 258), G1211R (SEQ ID NOS: 432, 430, 429, 428, 427, 426, 425, 424, 423, 422, 420, 418, 417, 416), M1249L (SEQ ID NOS: 562, 561, 560, 559, 558, 557, 556, 555, 554, 553, 552, 551, 550, 549, 548, 547, 546, 545, 544, 543, 542, 541, 540, 539), MGF505-9R (SEQ ID NOS: 733, 732, 731, 730, 729, 728, 727, 726), P1192R (SEQ ID NOS: 817, 816, 815, 814, 813, 812, 811, 810, 809, 808, 807, 806, 805, 804, 803, 802, 801), MGF505-1R (SEQ ID NOS: 692, 691, 690, 689, 688, 687, 686, 685, 684), MGF505-3R (SEQ ID NOS: 703, 702, 701, 700, 699), EP424R (SEQ ID NOS: 389, 388, 387, 386, 385, 384, 383, 382, 381, 380, 379), C475L (SEQ ID NOS: 201, 200, 199, 198, 197, 196, 195, 194, 193, 192, 191, 190, 189, 188), B602L (SEQ ID NOS: 75, 74, 73, 72, 71, 70, 69, 68, 67), CP530R (SEQ ID NOS: 278, 277, 276, 275), D339L (SEQ ID NOS: 322, 321, 320), D117L (SEQ ID NOS: 862, 864), I243L (SEQ ID NOS: 494, 493, 492, 491), I73R (SEQ ID NOS: 504, 503, 502), DP238L (SEQ ID NOS: 327, 326, 325), I9R (SEQ ID NOS: 513, 512, 511, 510), preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772,
724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570); and most preferably selected from the group consisting of: MGF505- 7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25).
8. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 7, wherein according to (c) the viral or bacterial vector comprises one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof, which encode one, two or more African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof, wherein the one, two or more African swine fever vims oligonucleotides and/or polynucleotides and or immunogenic fragments thereof comprise, preferably consist of, a nucleic acid sequence which is at least 70%, 75, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to a nucleic acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS:
858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26), A238L (SEQ ID NOS: 24, 22, 20, 18), MGF100-1L (SEQ ID NOS: 573, 571), K145R (SEQ ID NOS: 527, 525, 519, 517), B475L (SEQ ID NOS: 866, 867), H339R (SEQ ID NOS: 469, 467, 459, 457), I226R (SEQ ID NOS: 490, 488, 482, 480), CP2475L (p37) (SEQ ID NOS: 868, 869), CP2475L (pl50) (SEQ ID NOS: 870, 871), G1211R (SEQ ID NOS: 433, 431, 421, 419), M1249L (SEQ ID NOS: 872, 873), MGF505-9R (SEQ ID NOS: 874, 875), P1192R (SEQ ID NOS: 876, 877), MGF505-1R (SEQ ID NOS: 878, 879), MGF505-3R (SEQ ID NOS: 880, 881), EP424R (SEQ ID NOS: 882, 883), C475L (SEQ ID NOS: 884, 885), B602L (SEQ ID NOS: 886, 887), CP530R (SEQ ID NOS: 888, 889), D339L (SEQ ID NOS: 890, 891), D117L (SEQ ID NOS: 863, 865), I243L (SEQ ID NOS: 892, 893), I73R (SEQ ID NOS: 894, 895), DP238L (SEQ ID NOS: 896, 897), I9R (SEQ ID NOS: 898, 899); preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS:
859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS:
860, 27, 26), A238L (SEQ ID NOS: 24, 22, 20, 18), MGF100-1L (SEQ ID NOS: 573, 571); and most preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775,
773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26).
9. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 8, wherein the ASFV polypeptide is an ASFV full-length protein, preferably encoded by a polynucleotide sequence comprising, more preferably consisting of, any possible open reading frame (ORF), even more preferably encoded by a polynucleotide sequence comprising, most preferably consisting of, an open reading frame (ORF) with a 5' -end start codon and a 3' -end stop codon.
10. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any of claims 1 to 9, wherein the African swine fever vims is selected from the group consisting of: BA71, BA71ACD2 and/or Georgia 2007/1 strain(s).
11. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 10, wherein the immunogenicity (and/or immunological response) of the immunogenic composition or the vaccine or pharmaceutical composition or any comprised immunogenic fragment is indicated/characterized by an induced IFN-gamma response, preferably in a porcine IFN-gamma ELISpot assay, more preferably in a porcine IFN-gamma ELISpot assay as described in Example 1.
12. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 11 for use in a method of reducing or preventing the clinical signs or disease in porcines, preferably a pig, caused by an infection with at least one, preferably pathogenic, African swine fever vims or for use in a method of treating and/or preventing an infection with at least one, preferably pathogenic, African swine fever vims, wherein preferably said clinical signs or disease caused by an infection with at least one, preferably pathogenic, African swine fever vims or said infection with at least one, preferably pathogenic, African swine fever vims are selected from the group consisting of: African swine fever, acute African swine fever, chronic African swine fever, mortality, death, sudden death, fever, high fever, anorexia, lethargy, weakness, loss of appetite, recumbence, erythema, cyanotic skin blotching, diarrhea, constipation, abdominal pain, respiratory signs, coughing, vomiting, dyspnea, nasal and conjunctival discharges, hemorrhages, epistaxis, abortion, leukopenia, thrombocytopenia.
13. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 11 for use in a method of immunizing a porcine, preferably a pig, against a clinical disease caused by at least one, preferably pathogenic, African swine fever vims in said porcine, preferably pig, said method comprising the step of administering to the porcine, preferably pig, the immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 11, wherein said immunogenic composition or vaccine or pharmaceutical composition fails to cause clinical signs of infection but is capable of inducing an immune response that immunizes the porcine, preferably pig, against, preferably pathogenic forms of, said at least one African swine fever vims, wherein preferably said clinical disease or said clinical signs of infection are selected from the group consisting of: African swine fever, acute African swine fever, chronic African swine fever, mortality, death, sudden death, fever, high fever, anorexia, lethargy, weakness, loss of appetite, recumbence, erythema, cyanotic skin blotching, diarrhea, constipation, abdominal pain, respiratory signs, coughing, vomiting, dyspnea, nasal and conjunctival discharges, hemorrhages, epistaxis, abortion, leukopenia, thrombocytopenia.
14. The immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 11 for use in a method of prime-boost immunizing a porcine, preferably a pig, against a clinical disease caused by at least one, preferably pathogenic, African swine fever vims in said porcine, preferably pig, said method comprising the step of administering to the porcine, preferably pig, once or twice an immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 11 comprising (i) one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof as sole immunogenic components or (ii) a viral vector, preferably a recombinant and/or non-naturally occurring viral vector, comprising one, two or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof - as sole immunogenic component (priming step); and subsequently - after priming once or twice - administering to the porcine, preferably pig, a live attenuated African swine fever vims, preferably
B A71ACD2 (boosting step); wherein said immunogenic composition or vaccine or pharmaceutical composition as well as the live attenuated African swine fever vims independently from each other fail to cause clinical signs of infection but are capable of inducing an immune response that immunizes the porcine, preferably pig, against, preferably pathogenic forms of, said at least one African swine fever virus, wherein preferably said clinical disease or said clinical signs of infection are selected from the group consisting of: African swine fever, acute African swine fever, chronic African swine fever, mortality, death, sudden death, fever, high fever, anorexia, lethargy, weakness, loss of appetite, recumbence, erythema, cyanotic skin blotching, diarrhea, constipation, abdominal pain, respiratory signs, coughing, vomiting, dyspnea, nasal and conjunctival discharges, hemorrhages, epistaxis, abortion, leukopenia, thrombocytopenia.
15. A kit for vaccinating a porcine, preferably a pig, against a disease associated with and/or reducing the incidence or the severity of one or more clinical signs associated with or caused by at least one, preferably pathogenic, African swine fever vims in a porcine, preferably a pig, comprising:
(a) a dispenser capable of administering a vaccine to said porcine; and
(b) the immunogenic composition or the vaccine or pharmaceutical composition as claimed in any one of claims 1 to 11, and
(c) optionally, an instruction leaflet;
wherein preferably said disease or said clinical signs are selected from the group consisting of: African swine fever, acute African swine fever, chronic African swine fever, mortality, death, sudden death, fever, high fever, anorexia, lethargy, weakness, loss of appetite, recumbence, erythema, cyanotic skin blotching, diarrhea, constipation, abdominal pain, respiratory signs, coughing, vomiting, dyspnea, nasal and conjunctival discharges, hemorrhages, epistaxis, abortion, leukopenia, thrombocytopenia.
16. An African swine fever vims peptide and/or polypeptide, preferably full-length-protein, and/or
immunogenic fragment thereof comprising, preferably consisting of, an amino acid sequence, which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570), K145R (SEQ ID NOS: 526, 524, 523, 522, 521, 520, 518, 516, 515, 514), B475L (SEQ ID NOS: 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48), H339R (SEQ ID NOS: 468, 466, 465, 464, 463, 462, 461, 460, 458, 456, 455, 454), I226R (SEQ ID NOS: 489, 487, 486, 485, 484, 483, 481, 479, 478), CP2475L (p37) (SEQ ID NOS: 266, 265, 264, 263, 262, 261), CP2475L (pl50) (SEQ ID NOS: 260, 259, 258), G1211R (SEQ ID NOS: 432, 430, 429, 428, 427, 426, 425, 424, 423, 422, 420, 418, 417, 416), M1249L (SEQ ID NOS: 562, 561, 560, 559, 558, 557, 556, 555, 554, 553, 552, 551, 550, 549, 548, 547, 546, 545, 544, 543, 542, 541, 540, 539), MGF505-9R (SEQ ID NOS: 733, 732, 731, 730, 729, 728, 727, 726), P1192R (SEQ ID NOS: 817, 816, 815, 814, 813, 812, 811, 810, 809, 808, 807, 806, 805, 804, 803, 802, 801), MGF505-1R (SEQ ID NOS: 692, 691, 690, 689, 688, 687, 686, 685, 684), MGF505-3R (SEQ ID NOS: 703, 702, 701, 700, 699), EP424R (SEQ ID NOS: 389, 388, 387, 386, 385, 384, 383, 382, 381, 380, 379), C475L (SEQ ID NOS: 201, 200, 199, 198, 197, 196, 195, 194, 193, 192, 191, 190, 189, 188), B602L (SEQ ID NOS: 75, 74, 73, 72, 71, 70, 69, 68, 67), CP530R (SEQ ID NOS: 278, 277, 276, 275), D339L (SEQ ID NOS: 322, 321, 320), D117L (SEQ ID NOS: 862, 864), I243L (SEQ ID NOS: 494, 493, 492, 491), I73R (SEQ ID NOS: 504, 503, 502), DP238L (SEQ ID NOS: 327, 326, 325), I9R (SEQ ID NOS: 513, 512, 511, 510), preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25), A238L (SEQ ID NOS: 23, 21, 19, 17), MGF100-1L (SEQ ID NOS: 572, 570); and most preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722, 721, 719, 717), M448R (SEQ ID NOS: 568, 566, 565, 564, 563), D1133L (SEQ ID NOS: 297, 295, 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 274, 272, 269, 268, 267), A240L (SEQ ID NOS: 854, 853, 25).
17. The African swine fever vims peptide and/or polypeptide, preferably full-length-protein, and/or
immunogenic fragment thereof as claimed in claim 16, wherein the African swine fever vims polypeptides, preferably full-length proteins, comprise, preferably consist of, an amino acid sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 774, 772, 724, 722), M448R (SEQ ID NOS: 568, 566), D1133L (SEQ ID NOS: 297, 295), CP312R (SEQ ID NOS: 274, 272), A240L (SEQ ID NOS: 854, 853), A238L (SEQ ID NOS: 23, 21), MGF100-1L (SEQ ID NO: 572), K145R (SEQ ID NOS: 526, 524), B475L (SEQ ID NOS: 66, 65), H339R (SEQ ID NOS: 468, 466), I226R (SEQ ID NOS: 489, 487), CP2475 (SEQ ID NO: 257), CP2475 (SEQ ID NO: 256), G1211R (SEQ ID NOS: 432, 430), M1249L (SEQ ID NOS: 562, 561), MGF505-9R (SEQ ID NOS: 733, 732), P1192R (SEQ ID NOS: 817, 816), MGF505-1R (SEQ ID NOS: 692, 691), MGF505-3R (SEQ ID NOS: 703, 702), EP424R (SEQ ID NOS: 389, 388), C475L (SEQ ID NOS: 201, 200), B602L (SEQ ID NOS: 75, 74), CP530R (SEQ ID NOS: 278, 277), D339L (SEQ ID NOS: 322, 321), D117L (SEQ ID NOS: 862, 864), I243L (SEQ ID NOS: 494, 493), I73R (SEQ ID NOS: 504, 503), DP238L (SEQ ID NOS: 327, 326), I9R (SEQ ID NOS: 513, 512) and/or wherein the African swine fever vims peptides and/or immunogenic fragments thereof and/or African swine fever vims polypeptide/full-length protein immunogenic fragments comprise, preferably consist of, an amino acid sequence which is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 721, 719, 717), M448R (SEQ ID NOS: 565, 564, 563), D1133L (SEQ ID NOS: 294, 293, 292, 291, 290, 289, 287, 285, 284, 283, 282, 281), CP312R (SEQ ID NOS: 269, 268, 267), A240L (SEQ ID NO: 25), A238L (SEQ ID NOS: 19, 17), MGF100-1L (SEQ ID NO: 570), K145R (SEQ ID NOS: 523, 522, 521, 520, 518, 516, 515, 514), B475L (SEQ ID NOS: 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48), H339R (SEQ ID NOS: 465, 464, 463, 462, 461, 460, 458, 456, 455, 454), I226R (SEQ ID NOS: 486, 485, 484, 483, 481, 479, 478), CP2475L (p37) (SEQ ID NOS: 266, 265, 264, 263, 262, 261), CP2475L (pl50) (SEQ ID NOS: 260, 259, 258), G1211R (SEQ ID NOS: 429, 428, 427, 426, 425, 424, 423, 422, 420, 418, 417, 416), M1249L (SEQ ID NOS: 560, 559, 558, 557, 556, 555, 554, 553, 552, 551, 550, 549, 548, 547, 546, 545, 544, 543, 542, 541, 540, 539), MGF505-9R (SEQ ID NOS: 731, 730, 729, 728, 727, 726), P1192R (SEQ ID NOS: 815, 814, 813, 812, 811, 810, 809, 808, 807, 806, 805, 804, 803, 802, 801), MGF505-1R (SEQ ID NOS: 690, 689, 688, 687, 686, 685, 684), MGF505-3R (SEQ ID NOS: 701, 700, 699), EP424R (SEQ ID NOS: 387, 386, 385, 384, 383, 382, 381, 380, 379), C475L (SEQ ID NOS: 199, 198, 197, 196, 195, 194, 193, 192, 191, 190, 189, 188), B602L (SEQ ID NOS: 73, 72, 71, 70, 69, 68, 67), CP530R (SEQ ID NOS: 277, 276, 275), D339L (SEQ ID NO: 320), I243L (SEQ ID NOS: 492, 491), I73R (SEQ ID NO: 502), DP238L (SEQ ID NO: 325), I9R (SEQ ID NOS: 511, 510).
18. An African swine fever vims oligonucleotide and/or polynucleotide and/or immunogenic fragment
thereof encoding the African swine fever vims peptide and/or polypeptide, preferably full-length-protein, and/or immunogenic fragment thereof as claimed in any one of claims 16 to 17.
19. An African swine fever vims oligonucleotide and/or polynucleotide and/or immunogenic fragment
thereof encoding African swine fever vims peptides and/or polypeptides, preferably full-length proteins, and/or immunogenic fragments thereof; comprising, preferably consisting of, a nucleic acid sequence which is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99% or 100% identical to a nucleic acid sequence selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26), A238L (SEQ ID NOS: 24, 22, 20, 18), MGF100-1L (SEQ ID NOS: 573, 571), K145R (SEQ ID NOS: 527, 525, 519, 517), B475L (SEQ ID NOS: 866, 867), H339R (SEQ ID NOS:
469, 467, 459, 457), I226R (SEQ ID NOS: 490, 488, 482, 480), CP2475L (p37) (SEQ ID NOS: 868,
869), CP2475L (pl50) (SEQ ID NOS: 870, 871), G1211R (SEQ ID NOS: 433, 431, 421, 419), M1249L (SEQ ID NOS: 872, 873), MGF505-9R (SEQ ID NOS: 874, 875), P1192R (SEQ ID NOS: 876, 877), MGF505-1R (SEQ ID NOS: 878, 879), MGF505-3R (SEQ ID NOS: 880, 881), EP424R (SEQ ID NOS: 882, 883), C475L (SEQ ID NOS: 884, 885), B602L (SEQ ID NOS: 886, 887), CP530R (SEQ ID NOS: 888, 889), D339L (SEQ ID NOS: 890, 891), D117L (SEQ ID NOS: 863, 865), I243L (SEQ ID NOS:
892, 893), I73R (SEQ ID NOS: 894, 895), DP238L (SEQ ID NOS: 896, 897), I9R (SEQ ID NOS: 898, 899); preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26), A238L (SEQ ID NOS: 24, 22, 20, 18), MGF100-1L (SEQ ID NOS: 573, 571); and most preferably selected from the group consisting of: MGF505-7R/MGF505-8R (SEQ ID NOS: 857, 775, 773, 725, 723, 720, 718), M448R (SEQ ID NOS: 858, 569, 567), D1133L (SEQ ID NOS: 859, 298, 296, 288, 286), CP312R (SEQ ID NOS: 861, 273, 901, 900, 271, 270), A240L (SEQ ID NOS: 860, 27, 26).
20. The African swine fever vims peptide and/or polypeptide, preferably full-length-protein, and/or
immunogenic fragment thereof as claimed in any one of claims 16 to 17 or the African swine fever vims oligonucleotide and/or polynucleotide and/or immunogenic fragment thereof encoding African swine fever vims peptide and or polypeptide, preferably full-length-protein, and/or immunogenic fragments thereof as claimed in any one of claims 18 to 19, wherein the immunogenicity (and/or immunological response) of the immunogenic composition or the vaccine or pharmaceutical composition or any comprised immunogenic fragment is indicated/characterized by an induced IFN-gamma response, preferably in a porcine IFN-gamma ELISpot assay, more preferably in a porcine IFN-gamma ELISpot assay as described in Example 1.
21. The African swine fever vims peptide and/or polypeptide, preferably full-length-protein, and/or immunogenic fragment thereof as claimed in any one of claims 16 to 17 or the African swine fever vims oligonucleotide and/or polynucleotide and/or immunogenic fragment thereof encoding African swine fever vims peptide and/or polypeptide, preferably full-length-protein, and/or immunogenic fragments thereof as claimed in any one of claims 18 to 19, wherein the ASFV polypeptide is an ASFV full-length protein, preferably encoded by a polynucleotide sequence comprising, more preferably consisting of, any possible open reading frame (ORF), even more preferably encoded by a polynucleotide sequence comprising, most preferably consisting of, an open reading frame (ORF) with a 5' -end start codon and a 3' -end stop codon.
22. A viral or bacterial vector, preferably selected from the group consisting of: asfivims viral vector, avipox vims viral vector, canine morbillivims viral vector, herpes vims viral vector, varicella vims viral vector, Lawsonia spp., Salmonella spp., comprising one, two, three or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof as claimed in any one of claims 18 to 19.
23. A vector, preferably an expression vector, comprising one, two, three or more African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof as claimed in any one of claims 18 to 19.
24. The viral or bacterial vector as claimed in claim 22 or the vector as claimed in claim 23, comprising three African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof, preferably selected from EP402R, CP312R and A240L (multiepitope-I, ME-I), more preferably comprising, most preferably consisting of, the nucleic acid sequence selected from the group consisting of: SEQ ID NO: 855; or comprising thirteen African swine fever vims oligonucleotides and/or polynucleotides and/or immunogenic fragments thereof, preferably selected from D1133L, G1211R, M1249L, MGF505-9R, P1192R, CP2475L (pl50), B475L, EP424R, H339R, I226R, K145R, MGF505- 1R and CP2475L (p37) (multiepitope-II, ME-II), more preferably comprising, most preferably consisting of, the nucleic acid sequence selected from the group consisting of: SEQ ID NO: 856.
25. A host cell, preferably a mammalian host cell, comprising the viral or bacterial vector as claimed in any one of claims 22, 24 or the vector as claimed in any one of claims 23 to 24.
</claims>
</document>
